Clinical Study
Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up
Table 4
Serious Adverse Events (SAEs) during the three-year post-trial phase.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Patients randomized to receive either MMF or CsA treatment in the initial study phase. Determined by the treatment patients received at the end of the post-trial phase (mycophenolic acid derivative or not). Patients who received 2 g MMF per day and 50% of the initial CsA dose. Patients who received the usual CsA dose. Patients who received a treatment with a mycophenolic acid derivative at the end of the follow up phase. Patients without a mycophenolic acid derivative at the end of the follow up phase. Note: percentages were calculated based on the number of patients per group, nE: number of events, nP: number of patients. details of SAEs per system/organ were done for ones with an incidence 3%. |